Quarterly ResultMay 7, 2026, 04:16 PM
Ironwood Q1 Revenue +159% to $106.5M; Swings to $40.8M Net Income
AI Summary
Ironwood Pharmaceuticals reported a significant financial turnaround for Q1 2026, with collaborative arrangements revenue increasing by 159% to $106.5 million, up from $41.1 million in Q1 2025. The company swung from a net loss of $37.4 million in the prior year to a net income of $40.8 million, resulting in basic EPS of $0.25. This performance was primarily driven by strong LINZESS sales in the U.S. and reduced operating expenses.
Key Highlights
- Collaborative arrangements revenue increased 159% to $106.5 million in Q1 2026.
- Net income for Q1 2026 was $40.8 million, compared to a $37.4 million net loss in Q1 2025.
- Basic net income per share was $0.25 in Q1 2026, up from a $(0.23) loss per share.
- Cash and cash equivalents rose to $220.5 million as of March 31, 2026.
- LINZESS U.S. sales revenue reached $104.2 million in Q1 2026.
- Research and development expenses decreased to $21.9 million in Q1 2026.
- Selling, general and administrative expenses decreased to $12.0 million in Q1 2026.
- Restructuring costs were a net benefit of $(0.04) million in Q1 2026, down from $18.6 million.